AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

MEDS · NASDAQ · Medical - Distribution

DataMEDS AI

Pharmaceutical distributor, pharmacy operator and prescription-routing technology provider.

$0.9702

After-hours close−0.01 (−1.31%)

At close$0.9831(−15.97%)

Something off on this page? Send us feedback.

Profile

DataMEDS AI, Inc.MEDSHealth Care

Sells pharmaceuticals wholesale, dispenses prescriptions and provides logistics services, while its EinsteinRx hub routes and supports prescription fulfillment. Revenue is transaction-based across distribution, pharmacy sales and 3PL fees; its AI, blockchain and consumer-health additions remain under integration or rollout.

Combines pharmaceutical wholesale distribution, prescription fulfillment and technology-enabled clinical services in the United States. Wellgistics distributes branded and generic drugs and over-the-counter products to independent pharmacies, while Corexa Pharmacy fills and ships prescriptions. The company also earns 3PL fees for warehousing, inventory management, pick/pack and shipping for manufacturers.

EinsteinRx routes prescriptions between patients, prescribers, pharmacies, payors/PBMs and manufacturers while supporting eligibility verification, onboarding, adherence, prior authorization and cash-pay fulfillment. PharmacyChain and the Health Lives Here app are being integrated into that workflow, with broad public rollout of the app planned on a state-by-state basis.

Depends on pharmacy and wholesale licenses, PBM and insurer reimbursement, provider-network inclusion, product access, third-party technology services, and sustained working capital for inventory purchasing and fulfillment.

Company facts

CEOPrashant Patel and Gerald Commissiong

ListedFeb 21, 2025

ExchangeNASDAQ

HeadquartersTampa, FL

CountryUnited States

Employees27

CIK0002030763

ISINUS9495032057

Key statistics

Market cap$2.5M

EPS (ttm)−$47.13

P/E (ttm)−0.0204

ROE877.6%

P/B−0.1268

P/S0.3141

Dividend yield—

Beta1.82vs XLV 0.31

Year to date −95.5% · Average volume (30d) 251.1K

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate—

Reported−$3.26

Revenue

Estimate—

Reported$1.8M

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 17, 2026Q2 FY26	—	−$3.26	—	—	$1.8M	—	+0.68%
May 19, 2026Q1 FY26	—	−$3.50	—	—	$1.6M	—	−23.21%
Mar 20, 2026Q4 FY25	—	−$6.50	—	—	$1.7M	—	−8.03%
Nov 19, 2025Q3 FY25	—	−$0.44	—	—	$3.0M	—	−15.61%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$10.9M	$7.8M	$3.0M	$1.7M	$1.6M	$1.8M
Gross profit	$692.6K	$505.8K	$231.0K	−$10.3M	$170.2K	−$174.4K
Operating income	−$31.3M	−$5.5M	−$31.5M	−$12.8M	−$6.0M	−$7.3M
Net income	−$32.4M	−$6.7M	−$34.3M	−$27.9M	−$7.7M	−$18.4M
Diluted EPS	−$31.00	−$5.50	−$23.00	−$13.50	−$3.50	−$7.13
Gross margin	6.4%	6.5%	7.7%	-614.4%	10.9%	-9.8%
Operating margin	-288.6%	-70.6%	-1,047.1%	-766.0%	-385.7%	-412.7%

Fiscal years (4-quarter sums)FY24 $18.1M · FY25 $23.3M

Revenue by product · Q4 FY25

Product$1.0M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $2.5M · Total debt $32.6M · Total assets $32.8M · Shareholders' equity −$19.5M

Dividends

No dividends on record.

Ownership

Institutions —Insiders —

Shares outstanding 2.62M · Float 1.05M

This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.

Insider tradesForm 4

Nothing filed in the last 12 months.